Bone Therapeutics to Participate In Upcoming Key Investor and Partnering Conferences in Q4 2017

Gosselies, Belgium, 24 October 2017, 7am CEST – Bone Therapeutics (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it will participate in the following upcoming key investor and partnering conferences in the fourth quarter of 2017:


Date: 6-8 November 2017

Venue: Berlin, Germany

Jefferies 2017 London Healthcare Conference

Date: 15-16 November 2017

Venue: London, UK

Third National Congress on Regenerative Medicine

Date: 15-18 November 2017

Venue: Moscow, Russia

Bryan, Garnier & Co 5th Annual Healthcare Conference

Date: 16-17 November 2017

Venue: Paris, France

Invest Securities BioMed Event ®

Date: 19 December 2017

Venue: Paris, France


Bone Therapeutics will also welcome private investors at the following retail events:

Finance Avenue

Date: 18 November 2017

Venue: Brussels, Belgium

Salon Actionaria

Date: 23-24 November 2017

Venue: Paris, France


*    About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

Our primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at:

Back to news